SINGAPORE (Feb 4): Australia-based pharmaceutical company iX Biopharma may be at a turning point. Last September, it completed the Phase 2 study on its flagship product, Wafermine, a ketamine-based sublingual pain relief solution, with positive results. The company plans to seek an appointment with the US Food and Drug Administration by the first quarter this year to discuss its final-stage trial.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply